1. Home
  2. MRAM vs LPTX Comparison

MRAM vs LPTX Comparison

Compare MRAM & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRAM
  • LPTX
  • Stock Information
  • Founded
  • MRAM 2008
  • LPTX 2011
  • Country
  • MRAM United States
  • LPTX United States
  • Employees
  • MRAM 83
  • LPTX N/A
  • Industry
  • MRAM Semiconductors
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MRAM Technology
  • LPTX Health Care
  • Exchange
  • MRAM Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • MRAM 130.3M
  • LPTX 119.6M
  • IPO Year
  • MRAM 2016
  • LPTX N/A
  • Fundamental
  • Price
  • MRAM $5.93
  • LPTX $0.48
  • Analyst Decision
  • MRAM Strong Buy
  • LPTX Buy
  • Analyst Count
  • MRAM 2
  • LPTX 3
  • Target Price
  • MRAM $9.00
  • LPTX $8.50
  • AVG Volume (30 Days)
  • MRAM 83.0K
  • LPTX 1.5M
  • Earning Date
  • MRAM 02-26-2025
  • LPTX 03-17-2025
  • Dividend Yield
  • MRAM N/A
  • LPTX N/A
  • EPS Growth
  • MRAM N/A
  • LPTX N/A
  • EPS
  • MRAM 0.07
  • LPTX N/A
  • Revenue
  • MRAM $53,865,000.00
  • LPTX N/A
  • Revenue This Year
  • MRAM N/A
  • LPTX N/A
  • Revenue Next Year
  • MRAM $7.15
  • LPTX N/A
  • P/E Ratio
  • MRAM $83.85
  • LPTX N/A
  • Revenue Growth
  • MRAM N/A
  • LPTX N/A
  • 52 Week Low
  • MRAM $4.89
  • LPTX $0.47
  • 52 Week High
  • MRAM $9.39
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • MRAM 47.32
  • LPTX 19.00
  • Support Level
  • MRAM $5.60
  • LPTX $0.47
  • Resistance Level
  • MRAM $6.25
  • LPTX $0.53
  • Average True Range (ATR)
  • MRAM 0.18
  • LPTX 0.04
  • MACD
  • MRAM 0.04
  • LPTX 0.07
  • Stochastic Oscillator
  • MRAM 54.93
  • LPTX 7.42

About MRAM Everspin Technologies Inc.

Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA); and Asia-Pacific (APAC).

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: